Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 81 results for "Byetta"

Exclusive License Agreement with AstraZeneca in Respect of Bye...

To read more Press Release articles, click here. Share this Article Google Facebook LinkedIn Tweeter Related News Recent Reports Mapping the Patient Journey: Harnessing the power of big data and analytics (Ref. FirstWord Dossier) ... FirstWord Pharma, 1 month ago

Byetta drug market 2016 overview & development

Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy . ...
 SlideShare.net4 weeks ago

Next stop in AstraZeneca fire sale: China

Dive Brief: AstraZeneca has sold off licensing rights to its diabetes drugs Byetta and Bydureon in China, pocketing $50 million upfront from a subsidiary of the Chinese 3SBio as it continues to shed non-core assets. The deal could be worth another ...
 BioPharma Dive1 month ago AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China  FiercePharma1 month ago

AstraZeneca grants 3SBio Chinese rights to Byetta and Bydureon

AstraZeneca has granted Chinese biotech firm 3SBio an exclusive license to commercialize type
 Pharma Letter1 month ago 3SBIO : granted exclusive license of diabetes drugs  4 Traders1 month ago 3SBio Pays $100 Million To Market Two AstraZeneca PLC Diabetes Drugs In China  BioSpace1 month ago 3SBio (01530) wins AstraZeneca's exclusive license  InfocastFN.com1 month ago

Type 2 diabetes market to 2019 a shifting treatment algorithm and intensified competition expected to drive growth by 2019

Upcoming SlideShare Loading in … 5 1. Global Type 2 Diabetes Market has the Potential To Grow to Teach $38.8 Billion by 2019 "The Report Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to ...
 SlideShare.net1 day ago Quid - Voice of Patient - Diabetes Type II  SlideShare.net2 months ago

New drug application submitted for semaglutide for type 2 diabetes treatment

A new drug application was submitted to the FDA for the once-weekly glucagon-like peptide-1 analogue semaglutide for treatment in adults with type 2 diabetes, according to a press release from Novo Nordisk.Semaglutide, in combination with oral ...
 Healio1 day ago
FiercePharma

AstraZeneca's Tagrisso trounces chemo in late-stage trial

AstraZeneca's lung cancer med Tagrisso, a blockbuster hopeful and important pillar in the company's big sales ambitions, soundly beat chemo in a new Phase 3 trial, staving off cancer growth for more than twice as long as the older regimen. The ...
 FiercePharma2 days ago
Peoples Pharmacy

Did Victoza for Diabetes Damage the Pancreas?

Type 2 diabetes has become an epidemic in the US and around the world. Doctors can choose froma number ofmedications to treat it. Each medicinehas its own side effect profile. Both patients and doctors may need to become familiar with possible ...
 Peoples Pharmacy2 days ago Four Steps to Incorporating Diabetes Care  Review of Optometry3 weeks ago 5 Pharma Stocks in Focus on World Diabetes Day  Zacks.com3 weeks ago
[x]  
Seeking Alpha

Why I Just Bought Teva Pharmaceuticals

Teva Pharmaceuticals ( TEVA ) is the latest addition in my long / short portfolio, a portfolio that has served me well with a year to date return of 49%. While I don't particularly like investing in slow growers, I do occasionally pick some that pay ...
 Seeking Alpha3 days ago Buy The Global Generic Leader On The Cheap  Seeking Alpha3 weeks ago Edited Transcript of TEVA.TA earnings conference call or presentation 15-Nov-16 1:00pm GMT  Yahoo! Finance3 weeks ago Teva Pharmaceutical Industries (TEVA) Erez Vigodman on Q3 2016 Results - Earnings Call Transcript  Seeking Alpha3 weeks ago
FierceBiotech

Platypus venom could give rise to a new class of diabetes treatments

Australian scientists have found a potential new angle for diabetes treatment in the unlikeliest of places: the venom of the platypus and the echidna. These animals produce a stable version of the hormone glucagon-like peptide-1, which could lead to ...
 FierceBiotech1 week ago Platypus Venom Could Spur Diabetes Treatment  IFLScience1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less